For many rheumatology practices, infusions and injectable biologics are the largest source of revenue and the largest source of risk. A single claim can be worth thousands of dollars, and a small error on units or authorization can deny the whole thing.
The two lines on every infusion claim
1. Administration
- 96365 / 96366: intravenous infusion for therapy or prophylaxis, initial hour and each additional hour.
- 96413 / 96415: chemotherapy and other highly complex drug or biologic administration, initial hour and each additional hour. Medicare and many payers allow these for certain monoclonal antibodies and other biologic response modifiers; others don't. Follow each payer's written policy for each drug.
- Time matters: start and stop times must be in the record. Hydration or pushes given alongside the main infusion follow their own rules and are often bundled when concurrent.
2. The drug
- J-code and units: each J-code is defined per unit size, for example infliximab J1745 (per 10 mg), rituximab J9312 (per 10 mg) and abatacept J0129 (per 10 mg). Units = dose given ÷ unit size, rounded as the payer instructs.
- NDC: many payers require the 11-digit NDC, unit qualifier and quantity on the claim. A mismatch between NDC quantity and HCPCS units is a frequent CO-16 denial.
- JW / JZ: for drugs from single-dose containers, Medicare requires JW on a separate line for any amount discarded and JZ when nothing was discarded. Missing modifiers can trigger edits.
- Biosimilars: biosimilars have their own HCPCS codes. Billing the reference product's code for a biosimilar, or the reverse, will deny or price wrongly.
Prior authorization: where most big denials start
Biologics almost always need prior authorization, and many plans require step therapy (trying and failing a preferred drug first).
- Track authorization start and end dates and the number of doses approved.
- Re-authorize before the last approved dose, not after.
- Keep the clinical support ready: diagnosis, disease activity measures, prior therapies and why they failed or weren't tolerated.
- If the drug or dose changes, update the authorization before the next infusion.
Buy-and-bill underpayments
Practices that buy the drug and bill the payer carry the cost until they are paid. Watch for:
- Drug lines paid below the contracted drug rate (often defined relative to ASP or a fee schedule).
- Payment updates that lag behind quarterly drug pricing changes.
- Units silently reduced on the remittance.
Comparing each drug line to the contract is the only reliable way to find these. See how to spot underpayments.
Joint injections and same-day visits
- 20610 / 20611: major joint aspiration or injection without or with ultrasound guidance. Bill 20611 only when the ultrasound image and report are recorded.
- Drugs injected: corticosteroids and viscosupplements need their own J-codes and units.
- Modifier 25: an E/M on the same day as an injection needs a separately identifiable reason documented, or it will be bundled.
A pre-submission check for infusion claims
- Valid authorization covers this drug, dose and date
- Administration code family matches this payer's policy for this drug
- Start and stop times documented; units of time correct
- Drug units calculated from dose and unit size; NDC quantity matches
- JW or JZ applied for single-dose containers on Medicare claims
- Biosimilar vs reference product coded correctly
For how RAS supports rheumatology practices, see our rheumatology billing page.
Coding rules, HCPCS codes and payer policies change. Confirm current descriptors, NCCI edits and each payer's drug policy.
This article is general billing information, not legal or coding-compliance advice. Payer rules, CPT descriptors and federal guidance change; check the current versions for your claims.